While Neuralink regularly makes headlines, its competitor Paradromics has just reached a historic milestone: the temporary implantation of its brain-computer interface (BCI) Connexus in a human patient. This breakthrough, revealed by Wired, marks a turning point in the race for medical neurotechnologies.
A quick and promising clinical test
On May 14, 2025, a surgical team at the University of Michigan implanted the Connexus device in the temporal lobe of an epileptic patient during a procedure aimed at locating seizure foci. Removed after just 10 minutes, the implant successfully recorded electrical brain signals with precision, confirming its biological compatibility and therapeutic potential (Paradromics Press Release).
Unlike Neuralink’s invasive approaches, Paradromics uses an insertion tool similar to an EpiPen to position its microelectrodes. This method, considered less intrusive, could accelerate future procedures.
Connexus: a technology focused on restoring communication
Designed for people with paralysis, stroke, or ALS, Connexus aims to translate neural signals into synthetic speech or text. According to Hoodline, the device integrates 421 platinum microfilaments, thinner than a human hair, capable of detecting the activity of individual neurons.
“Patients’ neurons continue to function as they did before their paralysis, but they no longer communicate with the body,” explains Matt Angle, CEO of Paradromics, in an interview with CBS Austin.
Fierce competition with Neuralink
While Neuralink has already implanted three patients, its latest trial encountered technical issues, as reported by Fox Business. Paradromics is betting on a different approach:
- Modularity: Up to 4 interconnected implants for 1,600 recording channels.
- Durability: Designed for long-term use with biocompatible materials.
- Integrated AI: Algorithms decipher neural data in real time.
The announced price of the implant – approximately $100,000 – is initially aimed at the medical market, with commercialization expected by 2029 (Nairametrics).
Next steps: a clinical trial in 2025
With regulatory approval, Paradromics will launch a clinical study in late 2025 on patients unable to speak. Led by prominent figures such as Dr. David Brandman (UC Davis), this phase will evaluate the device’s safety and its effectiveness in restoring communication (Mass Device).
Ethical considerations and therapeutic hopes
As the BCI market is set to explode, questions persist about access to these costly technologies and their psychological impact. However, for the 5.8 million Americans suffering from speech disorders, Connexus represents a tangible hope for regaining communicative autonomy.
To learn more:
- Wired’s original article on Paradromics’ implant
- Connexus technical specifications (Paradromics website)
- Comparative analysis of BCIs by Bloomberg
- Medical perspectives on neural implants (TechStartups)
This breakthrough illustrates how the convergence between neurosurgery and AI is redefining the boundaries of regenerative medicine, offering a glimmer of hope where traditional treatments fail.